Skip to Content
Merck
  • Mechanisms underlying the renoprotective effect of GABA against ischaemia/reperfusion-induced renal injury in rats.

Mechanisms underlying the renoprotective effect of GABA against ischaemia/reperfusion-induced renal injury in rats.

Clinical and experimental pharmacology & physiology (2014-12-09)
Shuhei Kobuchi, Ryosuke Tanaka, Takuya Shintani, Rie Suzuki, Hidenobu Tsutsui, Mamoru Ohkita, Yasuo Matsumura, Kazuhide Ayajiki
ABSTRACT

Excitation of the renal sympathetic nervous system is important for the development of ischaemic acute kidney injury (AKI) in rats. We reported that intravenous treatment with GABA has preventive effects against ischaemia/reperfusion (I/R)-induced renal dysfunction with histological damage in rats; however, the mechanisms underlying these effects on renal injury remain unknown. Thus, the aim of the present study was to clarify how GABA mechanistically affects ischaemic AKI in rats. Ischaemic AKI was induced in rats by clamping the left renal artery and vein for 45 min and then reperfusing the kidney to produce I/R-induced injury. Treatment with the GABAB receptor antagonist CGP52432 (100 nmol/kg, i.v., or 1 nmol/kg, i.c.v.) abolished the suppressive effects of 50 μmol/kg, i.v., GABA on enhanced renal sympathetic nerve activity (RSNA) during ischaemia, leading to elimination of the renoprotective effects of GABA. Intracerebroventricular treatment with 0.5 μmol/kg GABA or i.v. treatment with 1 μmol/kg baclofen, a selective GABAB receptor agonist, prevented the I/R-induced renal injury equivalent to i.v. treatment with GABA. Conversely, i.v. treatment with 10 μmol/kg bicuculline, a GABAA receptor antagonist, failed to affect the preventive effects of GABA against ischaemic AKI. We therefore concluded that GABAB receptor stimulation in the central nervous system, rather than peripheral GABAB receptor stimulation, mediates the preventive effect of GABA against ischaemic AKI by suppressing the enhanced RSNA induced by renal ischaemia.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Hypophosphorous acid solution, 50 wt. % in H2O
Baclofen, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
(±)-Baclofen, ≥98% (HPLC), solid
Sigma-Aldrich
Creatinine, anhydrous, ≥98%
Supelco
Creatinine, Pharmaceutical Secondary Standard; Certified Reference Material